And AbbVie and Genmab scoop their ASH presentation with new data.
ApexOnco Front Page
Recent articles
The company adds royalty aggregation to its R&D business.
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Big pharma interest remains, but the mood is fast turning gloomy.
So who else could be interested in the oestrogen degrader?
The recently unveiled conjugate DS3610a is to start phase 1.
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
After menin, the company tries again with farnesyl transferase.
